XNASIMRX
Market cap68mUSD
Dec 23, Last price
2.20USD
1D
10.00%
1Q
-24.66%
IPO
-87.06%
Name
Immuneering Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-53m
L+8.50%
CFO
-49m
L+11.04%
Profile
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 317 -84.76% | 2,080 -10.02% | |||
Cost of revenue | 58,925 | 52,032 | 35,966 | ||
Unusual Expense (Income) | |||||
NOPBT | (58,925) | (51,715) | (33,886) | ||
NOPBT Margin | |||||
Operating Taxes | (1,232) | (307) | |||
Tax Rate | |||||
NOPAT | (58,925) | (50,483) | (33,579) | ||
Net income | (53,472) 8.50% | (49,282) 46.95% | (33,536) 96.81% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 28,200 | 19 | 120,319 | ||
BB yield | -13.50% | -0.01% | -28.27% | ||
| Debt | |||||
Debt current | 300 | 379 | 274 | ||
Long-term debt | 8,626 | 9,305 | 10,456 | ||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (76,740) | (95,841) | (139,466) | ||
| Cash flow | |||||
Cash from operating activities | (48,969) | (44,101) | (30,851) | ||
CAPEX | (343) | (742) | (61) | ||
Cash from investing activities | 7,296 | 41,831 | (75,616) | ||
Cash from financing activities | 28,441 | 19 | 144,265 | ||
FCF | (58,544) | (50,129) | (39,033) | ||
| Balance | |||||
Cash | 85,666 | 105,525 | 149,199 | ||
Long term investments | 997 | ||||
Excess cash | 85,666 | 105,509 | 150,092 | ||
Stockholders' equity | (163,230) | 122,257,492 | 166,645,536 | ||
Invested Capital | 258,269 | 9,183 | 11,253 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 28,417 | 26,387 | 26,320 | ||
Price | 7.35 51.55% | 4.85 -70.01% | 16.17 | ||
Market cap | 208,862 63.20% | 127,976 -69.93% | 425,598 | ||
EV | 132,122 | 122,399,418 | 166,990,964 | ||
EBITDA | (58,573) | (50,918) | (33,727) | ||
EV/EBITDA | |||||
Interest | 1,014 | ||||
Interest/NOPBT | |||||